By Colin Kellaher
Lexeo Therapeutics has hired Kyle Rasbach as chief financial officer of the clinical-stage genetic-medicine company.
Lexeo on Thursday said Rasbach, 44 years old, most recently served as chief business officer at Zentalis Pharmaceuticals.
The New York company said Rasbach will receive an initial annual base salary of $480,000 and a discretionary annual bonus with a target of up to 40% of his annualized salary for the preceding calendar year.
R. Nolan Townsend, Lexeo's chief executive, had been serving as the company's principal financial officer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 19, 2024 07:18 ET (12:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。